Efficacy of Micronized Purified Flavonoid Fraction-Based Venoactive Therapy After Endovenous Mechanochemical Obliteration: Prospective Comparative Study

Abstract

Background Endovenous interventions and minimally invasive open procedures are effective in the management of varicose veins, but can result in post-operative pain/discomfort.Objective The objective of this study was to evaluate the clinical efficacy of micronized purified flavonoid fraction venoactive therapy for postoperative pain, vein-specific symptoms, and quality of life in patients with varicose veins following an endovenous mechanochemical ablation procedure. Methods This prospective, observational, single-center study allocated patients into two groups: Group A, micronized purified flavonoid fraction 1000 mg once daily for 30 days; Group B, no venoactive drug prescribed (control). The Clinical-Etiology-Anatomy-Pathophysiology classification system for chronic venous disorders was used to assess varicose veins; a 10-point Visual Analog Scale assessed pain syndrome intensity; the Venous Clinical Severity Score measured overall varicose vein severity; and the Chronic Venous Insufficiency QoL Questionnaire measured total quality of life. Results The study enrolled 58 patients (mean age 36.9 ± 4.1 years; 24 men) with varicose veins of C2-C4 who underwent truncal mechanochemical ablation plus mini-phlebectomy or foam sclerotherapy. Group A had significantly lower pain syndrome at days 14 and 30 compared with Group B (1.76 vs 2.20, p = 0.039; 1.38 vs 2.07, p = 0.003, respectively), and clinical symptom severity at day 30 (2.67 vs 3.13, p = 0.05). Significant differences in quality-of-life scores existed between groups at days 14 and 30 (15.21 vs 18.75, p = 0.008; 12.98 vs 16.33, p = 0.001). No micronized, purified flavonoid, fraction-related adverse effects were observed. Conclusions Micronized purified flavonoid fraction-based venoactive adjuvant therapy after mechanochemical ablation alleviated pain, reduced the severity of symptoms, and improved the quality of life in patients with varicose veins.

Nutritional Health and Bioflavonoids

“…Several studies have focused on the effects of flavonoid intake on healthy individuals (Table 1) and patients with IBD (Table 2). Total Intake of MPFF 1 [17] 144 mg/day 147-260 mg/day * Significantly higher than men; ** significantly higher than CD group; 1 micronized purified flavonoid fraction, 1000 mg/day.…”

“…The total daily amount of flavonoids in the average Western diet ranges from 200-1000 mg/day and goes down to 144 mg/day in patients with inflammatory bowel disease (IBD) [17]. Teas like green tea and chamomile are the major sources of dietary flavonoids and contain 200-300 mg of apigenin (chamomile) and epigallocatechin gallate (EGCG) [18,19].…”

Efficacy of Ruscus aculeatus extract in chronic venous disease: a systematic literature review and meta-analysis

“…Основным показанием для назначения флеботропных препаратов являются симптомы, отек и трофические расстройства, связанные с венозной гипертензией [6,35]. Использование ВАП, обладающих противоотечным, противовоспалительным и венотонизирующим эффектами, способно облегчить течение восстановительного периода после приустьевого лигирования и стриппинга сафеновых вен, стволовой эндовенозной абляции и флебосклерозирующей терапии [47][48][49][50][51][52][53].…”

Current principles of symptomatic treatment of lymphovenous insufficiency

“…В ходе проведенных исследований, направленных на сравнение эффективности лечения немикронизированным и микронизированным диосмином, было выявлено улучшение показателей функциональных симптомов (тяжесть в ногах, парестезии и отеки) при использовании препаратов МОФФ. В ходе анкетирования пациентов, получавших 2 группы препаратов, было выявлено улучшение симптоматики у пациентов, получавших МОФФ, что соответствовало 50% снижению интенсивности основных симптомов [38].…”